Search Weight Loss Topics:

Page 1,295«..1020..1,2941,2951,2961,297..1,3001,310..»

Dementia warning: Including too much of this in your diet may increase your risk – Express

Posted: November 7, 2019 at 6:40 pm

Dementia is an umbrella term for a collection of symptoms associated with brain damage by diseases, which tends to affect people over the age of 65, although it is not a natural part of ageing. While there is no certain way to ward off dementia, research is increasingly suggesting a healthy lifestyle can help reduce a persons risk of developing dementia. The growing consensus among experts is that what is good heart is also good for the brain, which also means the dietary decisions that are bad for the heart may also be harmful for the brain.

High-salt intake, which can send a persons blood pressure reading soaring and raise the risk of developing cardiovascular complications, is a good example.

Further supporting evidence that what is good for the heart is also good for the brain, a new study published in Nature showed that a high-salt diet may impair cognitive function by causing a deficiency of the compound nitric oxide, which is vital for maintaining vascular health in the brain, according to Weill Cornell Medicine researchers.

The investigators sought to understand the series of events that occur between salt consumption and poor cognition and concluded that lowering salt intake and maintaining healthy blood vessels in the brain may "stave off" dementia.

"Our study proposes a new mechanism by which salt mediates cognitive impairment and also provides further evidence of a link between dietary habits and cognitive function," said lead study author Dr. Giuseppe Faraco, an assistant professor of research in neuroscience in the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine.

READ MORE:Dementia symptoms: Signs of early-onset Alzheimers disease

The new study advances research published last year in Nature Neuroscience by Dr. Faraco and senior author Dr. Costantino Iadecola, director of the Feil Family Brain and Mind Research Institute and the Anne Parrish Titzell Professor of Neurology at Weill Cornell Medicine.

The 2018 study found that a high-salt diet caused dementia in mice, showing that the rodents became unable to complete daily living tasks such as building their nests and had problems passing memory tests.

After ruling out the theory that high salt intake was restricting blood flow in the mice, the researchers posited that high salt consumption may cause tau proteins in the brain to become unstable.

The protein tau is known to form tangles in the areas of the brain important for memory and then move through the brain as symptoms progress, and increasing evidence suggests this process may be an underlying trigger of brain decline.

DON'T MISSDementia symptoms: Signs of frontotemporal dementia - are you at risk?[INSIGHT]Dementia symptoms: Early sign of Lewy body dementia when you sleep - are you at risk?[INSIGHT]Dementia symptoms: Early signs of one of the most common types - vascular dementia [INSIGHT]

Although further research on salt intake and cognition in humans is needed, the current mouse study is a further warning sign to regulate salt consumption, Dr. Iadecola said.

He continued: And the stuff that is bad for us doesn't come from a saltshaker, it comes from processed food and restaurant food.

"We've got to keep salt in check. It can alter the blood vessels of the brain and do so in a vicious way."

In addition to high-salt consumption, inactivity is another risk factor for heart disease that may also increase a persons risk of developing dementia.

As the NHS explains: A lack of regular physical activity can increase your risk of heart disease, becoming overweight or obese, and type 2 diabetes all of which are risk factors for dementia.

As the health body notes, older adults who don't exercise are also more likely to have problems with memory or thinking (known as cognitive abilities).

It recommends aiming for 150 minutes of moderate-intensity aerobic activity each week, such as brisk walking, cycling or dancing, and you should also do strengthening exercises twice a week, such as gardening or yoga to reduce your risk.

The result of an analysis of 11 studies investigating the link between middle-aged people and the effects of physical exercise on their thinking and memory in later life found that underlines the importance of regular exercise in reducing the risk of developing dementia.

As Alzheimers UK reports, the findings show that regular exercise can significantly reduce the risk of developing dementia by about 30 percent, and for Alzheimer's disease specifically, the risk was reduced by 45 percent.

One particular study looked at health behaviours of over 2,000 men in Wales, and followed them for 35 years.

Of the five behaviours that were assessed (regular exercise, not smoking, moderate alcohol intake, healthy body weight and healthy diet), exercise had the greatest effect in terms of reducing dementia risk.

Overall, people who followed four or five of the above behaviours were up to 60 percent less likely to develop dementia.

Read more here:
Dementia warning: Including too much of this in your diet may increase your risk - Express

Weight loss: This food can help you slim down fast – when is the best time to eat it? – Express

Posted: November 7, 2019 at 6:40 pm

Weight loss diets usually require slimmers to eat less but it is important they pick the right foods. Eating foods high in protein can help dieters lose weight and gain lean muscle, an expert revealed. Is there a best time to have it?

By eating foods high in protein, dieters can boost their weight loss results, Harry Aitken, sports scientist and PT, told Express.co.uk.

He said: A high protein diet is simply one that is rich in protein intake, and lower, than normal, in calories.

So you will be consuming lots of protein, whilst still maintaining reduced calories to ensure you are in a calorie deficit, burning more calories than youre eating.

READ MORE: Weight loss: Top five exercises for flat abs revealed - full workout plan here

When upping protein in the diet, slimmers can get it from a host of different foods.

Harry explained meat like chicken, beef, and pork, dairy products and eggs are all a good source of protein.

Vegetarian options like seeds, buts, beans like lentils and broad beans, tofu, and manufactured protein sources made from soya or mycoproteins can also be eaten.

DON'T MISS

These foods will keep hunger pains at bay and dieters are less likely to opt for unhealthy snacks.

This means those hoping to lose weight will notice the benefits adding a portion of protein into every meal.

High protein intake has been proven to keep you fuller for longer, and they have also been proven to reduce subsequent calorie intake, Harry added.

So this means that not only are your high protein means filling you up, and helping you stay full, but they also help to reduce you consuming more calories throughout the day.

A food that can keep you fuller for longer, without consisting of huge amounts of calories, when dieting is a fantastic solution to help you reduce your calorie intake.

Dieters will feel more satisfied and likely to stick to the meal plan they are following.

Harry explained: The problem with many diets is theyre often quite drastic, and they restrict food so much that people feel starving. By helping to keep you full, and therefore happy, you are much more likely to actually stick to the diet.

For those hoping to get into shape, following a high protein diet will also help build muscle and appear lean.

Go here to read the rest:
Weight loss: This food can help you slim down fast - when is the best time to eat it? - Express

Weight loss: This surprising food can help you burn fat fast – what can you eat? – Express

Posted: November 7, 2019 at 6:40 pm

To trim down the waistline, dieters can pick from a number of different weight loss diet plans. The keto, or ketogenic, diet is a popular choice for many slimmers and can help speed up fat burning results. However, an expert reveals the tips you must follow.

The low carb and high fat plan is thought to help promote fat loss, Elliot Upton, PT at ultimate performance and head of LiveUP online coaching, explained.

He told Express.co.uk: The idea of keto is to take in such a low amount of carbohydrates that your body switches to a metabolic state called 'ketosis' where it uses fat and ketones for fuel instead of glucose."

By following this plan, the body will start to burn through fat leaving those on the plan much trimmer.

READ MORE: Joe Wicks reveals simple workout plan to help burn fat - avoid making common mistake

Although many people may think they should avoid fat when trying to slim down, eating foods high in healthy fats could actually help them get into shape.

Pairing those foods with meals high in carbs and with a moderate protein content can give the best results.

Elliot added: People who follow the keto diet will eat a high proportion of their calories from fat, some protein and minimal or no intake from carbohydrates.

DON'T MISS

Common foods people eat on the keto diet tend to be anything with a high fat and low carbohydrate content, such as oils, cheese and dairy products, eggs, nuts and some fatty meats or fish.

If switching onto the plan, he explained why dieters much ensure they still eat enough nutrients.

Removing a food group can leave slimmers lacking in certain things and the expert explained how to compensate for this.

When you cut out an entire food group, there is the potential to be lacking in key nutrients, he said.

More here:
Weight loss: This surprising food can help you burn fat fast - what can you eat? - Express

High-Protein Diet: This Winter Salad Is A Healthy and Wholesome Mix Of Protein And Fibre – NDTV Food

Posted: November 7, 2019 at 6:40 pm

Carrots are considered to be a treasure trove of dietary fibres.

Highlights

For the longest time, salads have been dubbed as plain and boring. However, with an outburst of green and raw food cafes, people are warming up to the idea of salads. Salads need not be bland all the time; they could be a scrumptious fare too. Fresh, leafy greens, nuts, olive oil, eggs, chicken, salmon, your salad can contain a whole mix of healthy and yummy ingredients; you just need to look out and explore. Winters are here and we are more than excited to fill our pantry with all winter veggies and fruits. Carrots form a fundamental part of Indian winters. After all, who can say no to the greasy and good bowl of gajar ka halwa. However, carrots are so much more than that. They can prove to be an excellent salad ingredient because of their umpteen health benefits.

(Also Read:5 Salad Restaurants In Delhi-NCR You Must Try)

Being rich in vitamin A and lycopene, carrots help improve vision and eyesight. They are also enriched with silicon and vitamin C that may do wonders for your skin. The vitamin C present in carrots also helps bolster your immunity. Carrots are considered to be a treasure trove of dietary fibres. Fibre helps ease digestion and aid weight loss too. How you ask? Fibre takes a while to breakdown and digest, due to which it stays in your system a little longer. This is why you feel full for longer spell and keep yourself from indulging too often.

(Also Read:11 Best Vegetarian Salad Recipes | Easy Vegetarian Salad Recipes)

Another crucial component of a weight loss diet is protein. Protein also takes a while to digest. It helps check your cravings and regulate hunger hormone ghrelin. Chickpeas and moong beans are two of the best plant-based sources of protein that are present in most Indian household kitchens. Why not use them to make your own protein-rich vegetarian salad?

Ingredients:

1/4th cup moong dal boiled

1/4th cup of boiled chickpeas

2 cups of shredded carrots

2 teaspoon olive oil

teaspoon black pepper

teaspoon lemon juice

teaspoon honey

Method:

Ingredients

1. In a bowl add oil, and then put moong dal, carrots and chickpeas. Mix well.

2. Next, add black pepper, lemon juice and honey. Give the salad a good mix.

This salad is ideal for days you are looking for something wholesome and yummy. So bring together all the ingredients and get going!

(This content including advice provides generic information only. It is in no way a substitute for qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.)

See the original post:
High-Protein Diet: This Winter Salad Is A Healthy and Wholesome Mix Of Protein And Fibre - NDTV Food

Get Rid Of Harmful Belly Fat By Switching To This Diet – International Business Times

Posted: November 7, 2019 at 6:40 pm

One of the causes of visceral fat build-up is poor diet. The accumulation of this body fat within the abdominal cavity is considered dangerous as there is the risk of developing serious health conditions. To prevent this from happening, there is a need to make some changes to the diet.

Among the many diet plans available today, one that is seen to be the best in reducing visceral fat is a low-carb diet. The ketogenic or keto-diet, in particular, has been proven to be very effective in getting rid of visceral fat.

What is a Keto Diet?

The keto diet is a high-fat, low-carb diet with sufficient protein used by doctors as a treatment to manage epilepsy in children. The main feature of this diet is that it makes the body burn fats instead of carbohydrates. how to get rid of belly fat through a regular healthy diet Photo: Bru-nO - Pixabay

Similar to the Atkins diet, where the objective is to minimize carbohydrates intake, the keto diet does the same by cutting back on easy to digest carbs. This means sugary foods, soda, pastries, and white bread are out, which will then be replaced by fat.

How Does It Work?

With fewer carbs, the body goes into a metabolic state referred to as ketosis. Eating less than 50g of carbs per day can cause the body to run out of fuel that it can quickly use. Usually taking three to four days, the body then will start breaking down protein and fat to use as fuel, causing weight loss.

Research conducted with 28 obese and overweight adult volunteers found that those who observed a keto-diet lost more fat compared to those who followed a low-fat diet. More interestingly, those following a ketogenic diet were able to drastically reduce, in some cases, remove visceral fat from their bodies.

The study also proved that low-carb diets like keto-diet are very effective in weight loss programs and, more importantly, holds the key to removing the dangerous visceral fat. This is because low-carb diets act quickly to remove the bodys excess water, thus reducing insulin levels and at the same time, causing rapid weight loss.

In other studies that seek to compare low-fat with low-carb diets, researchers found that those who limit their carb intake lost more weight without going hungry. Researchers also revealed that the efficacy of low-carb diets could last up to six months compared to other weight loss diet plans.

View post:
Get Rid Of Harmful Belly Fat By Switching To This Diet - International Business Times

Testosterone Replacement Therapy Market Published by Leading Research Firm – Maxi Wire

Posted: November 6, 2019 at 1:48 pm

The globaltestosterone replacement therapy marketrides on the back of technology. As consumer focus shifts from access to comfort, players in the market for testosterone replacement therapy are looking at new opportunities to capitalize on the potential. This exclusive report from Transparency Market Research will take you through an extensive analysis of every aspect in the testosterone replacement therapy market that is critical for defining your success strategy. It offers prudent information on markets under currents, trends that will open new doors, factors that will remain important, challenges that need to be overcome, prevailing competition in the market, and the geographical landscape.

Based on a tested and proven research methodology, our research analysts bring to you fact-checked information. Besides presenting the current market figures, our analysts provide you with accurate forecasts that can be the game-changer for your winning strategies for tomorrow. On the other hand, our reports also offer tailor-made insights. Further, our reports are packed with experts viewpoints which are transcribed from interviews conducted by our analysts.

For Right Perspective & Competitive Insights,Request For A Sample Here

For every market, information on leading players can be the difference between success and failure, be it a prominent brand or not. Our reports cover every significant players in the global testosterone replacement therapy market providing information about the company profile, products, winning strategies and market revenues. Not just that, TMR also provides information on the competitive landscape, helping you understand what impacted in one company being the market leader and others not. It also explains on the companies imperatives that define their success in the global market for testosterone replacement therapy.

Healthcare, unlike most industries, is typical of the region. Humans have multiple races and hence their genetic makeups are different. As a result, one condition has different impacts depending on the region. Therefore, information on how consumer requirements are different in regional landscape of the global testosterone replacement therapy is provided her in the report. Further, the economic capabilities of a country has a huge impact on healthcare infrastructure. TMRs report analysis the current economic scenario and also brings to you information on affordability during the coming years.

To Clarify Your Doubts About The Report,Request A Brochure Here

From market share to region-specific strategies, the report covers it all. At the same time, players in the testosterone replacement therapy market who are looking to expand might want to assess the potential of a prospective region. Our reports can provide you with custom-made insights for specific regions in the global testosterone replacement therapy market. The geographical analysis also covers regions-specific factors that could turn out to be hurdle for growth in the coming years.

View original post here:
Testosterone Replacement Therapy Market Published by Leading Research Firm - Maxi Wire

Male Hypogonadism Market Expand at the Fastest CAGR of 3.7% Throughout the Forecast Quantity 2017-2026 – Zebvo

Posted: November 6, 2019 at 1:48 pm

According to Persistence Market Researchs new report, globalmale hypogonadism marketis slated to exhibit a steady expansion throughout the forecast period (2017-2026). Revenues from the global market for male hypogonadism are estimated to exceed US$ 3,300 Mn by 2026-end.

Governments Taking Initiatives to Spread Awareness about Male Hypogonadism Therapeutics

Lack of sex hormones, usually referred to as male hypogonadism has resulted into many health risks that include osteoporosis, heart disease, and cardiovascular diseases on the back of thinning of bones. Global male hypogonadism market comprises several patented brands that currently have high market penetration. Proliferation in geriatric population in tandem with rising incidences related to rheumatoid arthritis and obesity have been primary factors affecting prevalence of male hypogonadism globally. Mounting incidences of testosterone deficiency in male population is a key factor that prevalence of male hypogonadism has surged worldwide. Several governments around the world have been taking initiatives to spread the awareness on hypogonadism treatment procedures, for example testosterone replacement therapy (TST), in order to relieve the painful burden on patients and their families.

As low testosterone levels are increasingly associated with exacerbation of chronic conditions, it further results into disorders apropos to hypothalamic-pituitary-gonadal axis. Advent of TST has however enabled reduction in cases of male hypogonadism considerably. With growing awareness related to its treatment among patients, the market is likely to gain an uptick during the forecast period. Rising availability of the selective androgen receptor modulators (SARMs) has further sustained the market expansion. The development and high availability of SARMs has led toward the provision of improved treatment procedure to patients having androgen deficiencies, thereby influencing the market growth.

North America will continue to Dominate Global Male Hypogonadism Market

North America will continue to dominate the global male hypogonadism market, with more than one-third revenue share during the forecast period. In addition, revenues from the male hypogonadism market in North America will exhibit the fastest expansion through 2026, as compared to those from all the other regional segments comprised in the report. Europe and Asia-Pacific excluding Japan (APEJ) are also expected to remain lucrative for the male hypogonadism market. The market in APEJ will ride on a slightly higher CAGR than that in Europe through 2026.

Topical gels are expected to remain the most lucrative among drugs available for treatment of male hypogonadism globally, with sales projected to register the fastest expansion through 2026. Injectables will also remain a major revenue contributor to the market. Sales of injectable and transdermal patches are poised to reflect an equal CAGR through 2026.

Testosterone Replacement Therapy to Remain Preferred among Patients

Based on therapy, testosterone replacement therapy is expected to remain preferred among patients with male hypogonadism worldwide. Roughly 66% revenue share of the market is expected to be held by revenues from testosterone replacement therapy by 2026-end. Revenues from gonadotropin replacement therapy will remain slightly more than half revenues gained from testosterone replacement therapy throughout the forecast period.

Klinefelters syndrome is expected to remain the most prevalent disease type observed in the male hypogonadism market, and revenues from treatment of this disease will exceed US$ 1,800 Mn by 2026-end. Kallmann Syndrome and Pituitary Adenomas among disease types will also account for major revenue shares of the market by 2026-end.

Nature of global male hypogonadism market has been observed to be highly competitive. This can be mainly attributed to occupancy of many small as well as large suppliers. New companies entering the male hypogonadism market are leveraging opportunities related to treatment developments and innovations. Strategic alliances are likely to remain strong among vendors for producing and marketing drugs worldwide, thereby increasing their market reach. Active market players listed by PMRs report include Astrazeneca Plc., Merck & Co. Inc., Laboratories Genevrier, Bayer AG, Endo International Plc., Allergan Plc., Ferring, Finox Biotech, AbbVie Inc., Eli Lilly and Company Ltd., Teva Pharmaceutical Industries Ltd., and IBSA Institut Biochimque.

Here is the original post:
Male Hypogonadism Market Expand at the Fastest CAGR of 3.7% Throughout the Forecast Quantity 2017-2026 - Zebvo

Eli Lilly and Company (LLY) and AbbVie Inc. (NYSE:ABBV) Contrasting side by side – FinanceMercury

Posted: November 6, 2019 at 1:48 pm

This is therefore a comparing of the institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation in Eli Lilly and Company (NYSE:LLY) and AbbVie Inc. (NYSE:ABBV). The two are both Drug Manufacturers Major companies that compete with one another.

Valuation & Earnings

Table 1 showcases the gross revenue, earnings per share and valuation of Eli Lilly and Company and AbbVie Inc. AbbVie Inc. appears to has lower revenue, but higher earnings than Eli Lilly and Company. Business that currently has a higher P/E ratio means that it is the more expensive of the two businesses. Eli Lilly and Company is currently more expensive than AbbVie Inc., because its trading at a higher P/E ratio.

Profitability

Table 2 demonstrates the return on equity, net margins and return on assets of Eli Lilly and Company and AbbVie Inc.

Risk & Volatility

A beta of 0.18 shows that Eli Lilly and Company is 82.00% less volatile than Standard & Poors 500. AbbVie Inc.s 8.00% less volatile than Standard & Poors 500 volatility due to the companys 0.92 beta.

Liquidity

Eli Lilly and Companys Current Ratio and Quick Ratio are 1.1 and 0.8 respectively. The Current Ratio and Quick Ratio of its competitor AbbVie Inc. are 1 and 0.9 respectively. Eli Lilly and Company therefore has a better chance of paying off short and long-term obligations compared to AbbVie Inc.

Analyst Ratings

The Recommendations and Ratings for Eli Lilly and Company and AbbVie Inc. are featured in the next table.

The consensus target price of Eli Lilly and Company is $130.25, with potential upside of 17.08%. Competitively AbbVie Inc. has an average target price of $81.33, with potential downside of -0.62%. The data from earlier shows that analysts view suggest that Eli Lilly and Company seems more appealing than AbbVie Inc.

Insider and Institutional Ownership

Institutional investors owned 83.7% of Eli Lilly and Company shares and 71% of AbbVie Inc. shares. Eli Lilly and Companys share owned by insiders are 12.1%. Insiders Comparatively, owned 0.1% of AbbVie Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Eli Lilly and Companys stock price has smaller decline than AbbVie Inc.

Summary

Eli Lilly and Company beats on 10 of the 15 factors AbbVie Inc.

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia; and migraine headaches. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, and heartworm diseases, as well as controls intestinal parasite infections. Additionally, the company offers vaccinev to prevent Lyme disease, bronchial infections, rabies, and various infectious diseases in dogs, cats, and horses. It has collaboration agreements with Daiichi Sankyo Co., Ltd., Incyte Corporation, Pfizer Inc., AstraZeneca, William Sansum Diabetes Center, Purdue University, and Nektar Therapeutics. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus(HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinsons disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has collaboration agreements with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; M2Gen; and Principia Biopharma Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

View original post here:
Eli Lilly and Company (LLY) and AbbVie Inc. (NYSE:ABBV) Contrasting side by side - FinanceMercury

Male Hypogonadism Market to Raise at a CAGR of 3.7% Over the Forecast Quantity 2017-2026 – Lake Shore Gazette

Posted: November 6, 2019 at 1:48 pm

According to Persistence Market Researchs new report, globalmale hypogonadism marketis slated to exhibit a steady expansion throughout the forecast period (2017-2026). Revenues from the global market for male hypogonadism are estimated to exceed US$ 3,300 Mn by 2026-end.

Governments Taking Initiatives to Spread Awareness about Male Hypogonadism Therapeutics

Lack of sex hormones, usually referred to as male hypogonadism has resulted into many health risks that include osteoporosis, heart disease, and cardiovascular diseases on the back of thinning of bones. Global male hypogonadism market comprises several patented brands that currently have high market penetration. Proliferation in geriatric population in tandem with rising incidences related to rheumatoid arthritis and obesity have been primary factors affecting prevalence of male hypogonadism globally. Mounting incidences of testosterone deficiency in male population is a key factor that prevalence of male hypogonadism has surged worldwide. Several governments around the world have been taking initiatives to spread the awareness on hypogonadism treatment procedures, for example testosterone replacement therapy (TST), in order to relieve the painful burden on patients and their families.

As low testosterone levels are increasingly associated with exacerbation of chronic conditions, it further results into disorders apropos to hypothalamic-pituitary-gonadal axis. Advent of TST has however enabled reduction in cases of male hypogonadism considerably. With growing awareness related to its treatment among patients, the market is likely to gain an uptick during the forecast period. Rising availability of the selective androgen receptor modulators (SARMs) has further sustained the market expansion. The development and high availability of SARMs has led toward the provision of improved treatment procedure to patients having androgen deficiencies, thereby influencing the market growth.

North America will continue to Dominate Global Male Hypogonadism Market

North America will continue to dominate the global male hypogonadism market, with more than one-third revenue share during the forecast period. In addition, revenues from the male hypogonadism market in North America will exhibit the fastest expansion through 2026, as compared to those from all the other regional segments comprised in the report. Europe and Asia-Pacific excluding Japan (APEJ) are also expected to remain lucrative for the male hypogonadism market. The market in APEJ will ride on a slightly higher CAGR than that in Europe through 2026.

Topical gels are expected to remain the most lucrative among drugs available for treatment of male hypogonadism globally, with sales projected to register the fastest expansion through 2026. Injectables will also remain a major revenue contributor to the market. Sales of injectable and transdermal patches are poised to reflect an equal CAGR through 2026.

Testosterone Replacement Therapy to Remain Preferred among Patients

Based on therapy, testosterone replacement therapy is expected to remain preferred among patients with male hypogonadism worldwide. Roughly 66% revenue share of the market is expected to be held by revenues from testosterone replacement therapy by 2026-end. Revenues from gonadotropin replacement therapy will remain slightly more than half revenues gained from testosterone replacement therapy throughout the forecast period.

Klinefelters syndrome is expected to remain the most prevalent disease type observed in the male hypogonadism market, and revenues from treatment of this disease will exceed US$ 1,800 Mn by 2026-end. Kallmann Syndrome and Pituitary Adenomas among disease types will also account for major revenue shares of the market by 2026-end.

Nature of global male hypogonadism market has been observed to be highly competitive. This can be mainly attributed to occupancy of many small as well as large suppliers. New companies entering the male hypogonadism market are leveraging opportunities related to treatment developments and innovations. Strategic alliances are likely to remain strong among vendors for producing and marketing drugs worldwide, thereby increasing their market reach. Active market players listed by PMRs report include Astrazeneca Plc., Merck & Co. Inc., Laboratories Genevrier, Bayer AG, Endo International Plc., Allergan Plc., Ferring, Finox Biotech, AbbVie Inc., Eli Lilly and Company Ltd., Teva Pharmaceutical Industries Ltd., and IBSA Institut Biochimque.

Read more:
Male Hypogonadism Market to Raise at a CAGR of 3.7% Over the Forecast Quantity 2017-2026 - Lake Shore Gazette

What Is Clean Fasting, and How Will It Help You Speed Up Weight Loss? – POPSUGAR

Posted: November 6, 2019 at 1:47 pm

No matter what intermittent fasting schedule you're on, if you found that you're not losing weight or you've hit a weight-loss plateau, it could be because you're not clean fasting.

According to cardiologist and weight management expert Luize Petre, MD, intermittent fasting involves alternating periods of eating, or "feasting," with periods of not eating, or "fasting." The fasting window can be done in various ways, either with allowance of very low-caloric foods or liquids or by restricting it to only zero-calorie liquids. "When the more restrictive approach is taken, that is called clean fasting," she explained.

Clean fasting often is used to describe fasting or time-restricted feeding where only calorie-free and unsweetened beverages are consumed; in other words, Erin Donaldson, DO, with Executive Medicine of Texas, said stick to water, sparkling water, black coffee, tea, and herbal teas with nothing else added not even lemon slices or a noncaloric natural sweetener like stevia or monk fruit.

Many experts will say a little cream, MCT oil, sugar-free sweetener, or stevia is OK to have in your coffee while fasting, also known as "dirty fasting." But for maximum results, especially if you're not achieving your weight-loss goals, "the fast should be kept clean, and all artificial sweeteners should be avoided," said Dr. Donaldson.

Dr. Petre adds that sugar-free sweeteners can raise your insulin levels initially, and that's because your taste buds tell the brain that sugar is coming and the body prepares in advance for insulin secretion. Studies suggest that stevia can also raise insulin levels, so that should be avoided as well.

When insulin levels are low, it cues our bodies to use stored fat for energy, explained Dr. Donaldson. And even though you think you're still fasting because you're only drinking coffee with a little sugar-free sweetener or cream, or you're consuming something under 35 calories, if your body produces insulin, then it won't turn to your stored fat for energy.

Your body will have the same response to sugar-free beverages such as sodas and sports drinks, said Dr. Petre, so it's best to avoid these as well and stick to clean fasting.

If gum is sweetened with artificial sweeteners, then yes, it could also trigger insulin secretion as discussed above due to the taste buds and brain connection, explained Dr. Petre.

Another issue with chewing gum or consuming a sugar-free beverage while fasting, explained Dr. Jason Fung, MD, a nephrologist (kidney specialist) and author of The Complete Guide to Fasting, is that "gum is usually not recommended because the act of chewing and the sweetness usually triggers salivation and hunger." So for some, even if you chew sugarless gum or drink a diet soda, it might actually make fasting harder.

Don Brown, MD, CEO and founder of the LIFE Fasting app, said "the popular concept of clean fasting doesn't necessarily have a strong scientific rationale." The important thing is that in clinical research studies, even when people consume a small number of calories, flavored water, broth, or other artificially sweetened, calorie-free beverages while fasting, intermittent fasting for periods of 16 or more hours has been shown to have measurable health benefits.

If you're feeling great intermittent fasting and sipping on coffee with a little cream and stevia, chewing gum, or drinking sugar-free beverages, then I say that's a win! But if you're not feeling great or achieving the weight-loss results you want, it's worth trying clean fasting.

See original here:
What Is Clean Fasting, and How Will It Help You Speed Up Weight Loss? - POPSUGAR


Page 1,295«..1020..1,2941,2951,2961,297..1,3001,310..»